Subscribe
Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

JAMA Editor’s Summary

Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

Editor's Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the
December 22, 2020
ADVERTISEMENT
WP Engine Wordpress Hosting

Digoxin vs Bisoprolol for AFib, Risk of Second Cancer After a First Cancer, Review of GERD and more

Editor’s Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the December 22/29, 2020 issue

ADVERTISEMENT
TransferWise

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Proudly supported by:

cover
Supporting Diversity in Healthtech Investment (Dr. Fiona Pathiraja) Diversity is an increasingly debated topic in startup investments, since founders of under-represented backgrounds may it be gender, race, age, and more too often experience inequality in opportunities.